Giuseppe Di Pietro

Dr. Giuseppe Di Pietro

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
GSGiulia Di Stefano
Giulia Di Stefano
ALAndrea Di Lionardo
Andrea Di Lionardo
GPGiuseppe Di Pietro
Giuseppe Di Pietro
ATAndrea Truini
Andrea Truini
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system. Neuropathic pain represents a broad category of pain conditions, common complications of peripheral neuropathies, which are characterized by a combination of positive symptoms, including paresthesia and/or dysesthesia and sensory deficits in the painful area. In the present paper, we aimed to assess neuropathic pain frequency and clinical characteristics of peripheral neuropathies due to different aetiologies according to grading system criteria of the International Association for the Study of Pain for a definitive diagnosis of neuropathic pain. Epidemiological studies applying these criteria have been conducted in patients with diabetes, brachial plexus injury, and other traumatic nerve injuries. Neuropathic pain was diagnosed in 37–42% of patients with diabetic peripheral neuropathy, 56% of patients with brachial plexus injury, and 22% of patients with intercostobrachial neuropathy. The most frequent neuropathic pain type was ongoing pain (described as burning or pressing), followed by paroxysmal pain (electric shock-like sensations) and allodynia (pain evoked by brushing and pressure). By providing information on the frequency, clinical signs, and variables associated with neuropathic pain due to different aetiologies, these studies contribute to improving the clinical management of this condition.

1 December 2021 in Neurophysiologie Clinique
Verified
Journal Article
Open access
GPGiuseppe Di Pietro
Giuseppe Di Pietro
GSGiulia Di Stefano
Giulia Di Stefano
CLCaterina Leone
Caterina Leone
ALAndrea Di Lionardo
Andrea Di Lionardo
ESEmanuele Sgro
Emanuele Sgro
ATAndrea Truini
Andrea Truini
Although somatosensory evoked potentials (SEPs) after median nerve stimulation are widely used in clinical practice, the dorsal horn generator of the N13 SEP spinal component is not clearly understood. To verify whether wide dynamic range neurons in the dorsal horn of the spinal cord are involved in the generation of the N13 SEP, we tested the effect of heterotopic noxious conditioning stimulation, which modulates wide dynamic range neurons, on N13 SEP in healthy humans. In 12 healthy subjects, we performed the cold pressor test on the left foot as a heterotopic noxious conditioning stimulus to modulate wide dynamic range neurons. To verify the effectiveness of heterotopic noxious conditioning stimulation, we tested the pressure pain threshold at the thenar muscles of the right hand and recorded SEPs after right median nerve stimulation before, during and after the cold pressor test. The cold pressor test increased pressure pain threshold by 15% (p = 0.04). During the cold pressor test, the amplitude of the N13 component was significantly lower than that recorded at baseline (by 25%, p = 0.04). In this neurophysiological study in healthy humans, we showed that a heterotopic noxious conditioning stimulus significantly reduced N13 SEP amplitude. This finding suggests that the N13 SEP might be generated by the segmental postsynaptic response of dorsal horn wide dynamic range neurons.

5 October 2022 in Journal of the Peripheral Nervous System
Verified
Journal Article
Open access
EGEleonora Galosi
Eleonora Galosi
PFPietro Falco
Pietro Falco
GPGiuseppe Di Pietro
Giuseppe Di Pietro
CLCaterina Leone
Caterina Leone
NENicoletta Esposito
Nicoletta Esposito
ATAndrea Truini
Andrea Truini
A definite diagnosis of pure small fiber neuropathy (SFN) relies on specific diagnostic testing, such as skin biopsy, quantitative sensory testing (QST), and nociceptive evoked potentials, which require considerable resources that may not be widely available. Accordingly, diagnostic tools with easy implementation in non‐specialist centers are warranted to identify patients who require second‐level diagnostic tests. In this study, we aimed to test the accuracy of the Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN‐SIQ) in diagnosing pure SFN. We enrolled 86 patients with suspected pure SFN. In these patients, we calculated the diagnostic accuracy of the SFN‐SIQ using a combination of clinical examination, QST, and skin biopsy as a reference standard. We found that the SFN‐SIQ showed an excellent ability to discriminate between patients with and without pure SFN, with 86% sensitivity and 70% specificity in the diagnosis of pure SFN. Our study providing the diagnostic yield of the SFN‐SIQ for pure SFN diagnosis suggests that this questionnaire might be used to screen patients with suspected SFN and identify those requiring second‐level diagnostic tests such as QST, skin biopsy, or nociceptive evoked potentials.

29 July 2023 in The Journal of Pain
Verified
Journal Article
Closed access
PFPietro Falco
Pietro Falco
EGEleonora Galosi
Eleonora Galosi
GSGiulia Di Stefano
Giulia Di Stefano
Caterina LeoneCaterina Leone
Caterina Leone
GPGiuseppe Di Pietro
Giuseppe Di Pietro
ATAndrea Truini
Andrea Truini

1 September 2023 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
GSGianfranco De Stefano
Gianfranco De Stefano
GPGiuseppe Di Pietro
Giuseppe Di Pietro
ATAndrea Truini
Andrea Truini
GCGiorgio Cruccu
Giorgio Cruccu
GSGiulia Di Stefano
Giulia Di Stefano
Despite the exemplary efficacy of voltage-gated sodium channel blockers as a first-line treatment of trigeminal neuralgia, the pharmacological management of this excruciating facial pain condition remains a major issue, as these first-line drugs produce intolerable side effects in a significant portion of patients. In addition, in patients with concomitant continuous pain, the efficacy of these drugs may drop, thus suggesting the opportunity to test the efficacy of different drug categories. The aim of this review is to provide current, evidence-based, knowledge about the use of gabapentin and other α 2δ ligands in patients with trigeminal neuralgia. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials database (ClinicalTrials.gov), considering publications up to April 2023. Two authors independently selected studies for inclusion and data extraction. The efficacy of α 2δ ligands, gabapentin and pregabalin, has been assessed in seven controlled or open-label studies. Despite the low quality of evidence, the favorable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia. Plain Language Summary: Trigeminal neuralgia is a really excruciating neuropathic pain condition. Although sodium channel blockers are efficacious in most of the patients, the poor tolerability profile and the limited efficacy in patients with concomitant continuous pain represent a major issue over the long-term treatment. Gabapentin and other α 2δ ligands, which have been shown to be effective in the treatment of other neuropathic conditions characterized by continuous pain, may be tried as additional agents along with sodium channel blockers. In this review, based on a systematic search of relevant literature, we aim to provide current, evidence-based, knowledge about the use of gabapentin and other α 2δ ligands in patients with trigeminal neuralgia. The favourable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia.

2 February 2024 in Clinical Neurophysiology
Verified
Journal Article
Open access
GPGiuseppe Di Pietro
Giuseppe Di Pietro
ECE Cioffi
E Cioffi
PFP Falco
P Falco
EGE Galosi
E Galosi
GSG De Stefano
G De Stefano
ATA Truini
A Truini
In Friedreich's ataxia research, the focus is on discovering treatments and biomarkers to assess disease severity and treatment effects. Our study examines high-resolution nerve ultrasound in these patients, seeking correlations with established clinical markers of disease severity. Ten patients with Friedreich's Ataxia underwent a comprehensive clinical assessment with established scales (SARA, FARS, mFARS, INCAT, ADL 0-36, IADL). Additionally, they underwent nerve conduction studies and high-resolution nerve ultrasound. Quantitative evaluation of nerve cross-sectional area, conducted at 24 nerve sites using high-resolution nerve ultrasound, was compared with data obtained from 20 healthy volunteers. All the patients had a severe sensory axonal neuropathy. High-resolution nerve ultrasound showed significant increase, in cross sectional area, of median and ulnar nerves at the axilla and arm. The cumulative count of affected nerve sites was directly associated with clinical disability, as determined by SARA, FARS, mFARS, ADL 0-36, and INCAT score, while displaying an inverse correlation with IADL. Our study shows that high-resolution ultrasound reveals notable nerve abnormalities, primarily in the upper limbs of patients diagnosed with Friedreich's Ataxia. The observed correlation between these nerve abnormalities and clinical disability scales indicates the potential use of this technique as a biomarker for evaluating disease severity and treatment effects. Nerve Ultrasound is a potential biomarker of disease severity in Friedreich's Ataxia.